You just read:

New analysis estimates the positive impact of empagliflozin on prolonging life expectancy in adults with type 2 diabetes and established cardiovascular disease

News provided by

Boehringer Ingelheim (Canada) Ltd.

Nov 06, 2018, 08:00 ET